Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial

Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial

Background: A vaccine against SARS-CoV-2 is of high urgency. Here the safety and immunogenicity induced by a DNA vaccine (INO-4800) targeting the full length spike antigen of SARS-CoV-2 are described. Methods: INO-4800 was evaluated in two groups of 20 participants, receiving either 1.0 mg or 2.0 mg...

Full description

Bibliographic Details
Main Authors: Pablo Tebas, ShuPing Yang, Jean D. Boyer, Emma L. Reuschel, Ami Patel, Aaron Christensen-Quick, Viviane M. Andrade, Matthew P. Morrow, Kimberly Kraynyak, Joseph Agnes, Mansi Purwar, Albert Sylvester, Jan Pawlicki, Elisabeth Gillespie, Igor Maricic, Faraz I. Zaidi, Kevin Y. Kim, Yaya Dia, Drew Frase, Patrick Pezzoli, Katherine Schultheis, Trevor R.F. Smith, Stephanie J. Ramos, Trevor McMullan, Karen Buttigieg, Miles W. Carroll, John Ervin, Malissa C. Diehl, Elliott Blackwood, Mammen P. Mammen, Jessica Lee, Michael J. Dallas, Ami Shah Brown, Jacqueline E. Shea, J.Joseph Kim, David B. Weiner, Kate E. Broderick, Laurent M. Humeau
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:EClinicalMedicine
Subjects:
SARS-CoV-2
COVID-19
DNA vaccine
INO-4800
Phase 1
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537020304338

Internet

http://www.sciencedirect.com/science/article/pii/S2589537020304338

Similar Items